The natural history of malignancies under conditions of BRAF inhibitor stimulation.
Robert M
RM
White
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000494:pharmacology*; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics; D012307:Risk Factors; D012878:Skin Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology*; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf